Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection
Koen Vandyck, Jérôme Deval
Current Opinion in Virology (2021) Vol. 49, pp. 36-40
Open Access | Times Cited: 129

Showing 1-25 of 129 citing articles:

Advances in covalent drug discovery
Lydia Boike, Nathaniel J. Henning, Daniel K. Nomura
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 12, pp. 881-898
Open Access | Times Cited: 459
Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332
Yao Zhao, Chao Fang, Qi Zhang, et al.
Protein & Cell (2021) Vol. 13, Iss. 9, pp. 689-693
Open Access | Times Cited: 207
The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor In Vitro and Confer Resistance To Nirmatrelvir
Dirk Jochmans, Liu C, Kim Donckers, et al.
mBio (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 127
Paxlovid: Mechanism of Action, Synthesis, and In Silico Study
Mahrokh Marzi, Mohammad Kazem Vakil, Maryam Bahmanyar, et al.
BioMed Research International (2022) Vol. 2022, pp. 1-16
Open Access | Times Cited: 103
Molnupiravir and Its Antiviral Activity Against COVID-19
Lili Tian, Zehan Pang, Maochen Li, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 102
The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations
Ryan Joyce, Vivian W. Hu, Jun Wang
Medicinal Chemistry Research (2022) Vol. 31, Iss. 10, pp. 1637-1646
Open Access | Times Cited: 92
Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?
Yuan‐Pin Hung, Jen‐Chieh Lee, Chun-Wei Chiu, et al.
Antibiotics (2022) Vol. 11, Iss. 2, pp. 220-220
Open Access | Times Cited: 89
Therapeutics for COVID-19 and post COVID-19 complications: An update
Debdoot Basu, Vivek P. Chavda, Anita A. Mehta
Current Research in Pharmacology and Drug Discovery (2022) Vol. 3, pp. 100086-100086
Open Access | Times Cited: 68
Inhibition of the main protease of SARS-CoV-2 (Mpro) by repurposing/designing drug-like substances and utilizing nature’s toolbox of bioactive compounds
Io Antonopoulou, Eleftheria Sapountzaki, Ulrika Rova, et al.
Computational and Structural Biotechnology Journal (2022) Vol. 20, pp. 1306-1344
Open Access | Times Cited: 67
Cys44 of SARS-CoV-2 3CLpro affects its catalytic activity
Ilaria Iacobucci, Irene Cipollone, Flora Cozzolino, et al.
International Journal of Biological Macromolecules (2025), pp. 139590-139590
Closed Access | Times Cited: 1
Structural and Biochemical Analysis of the Dual Inhibition of MG-132 against SARS-CoV-2 Main Protease (Mpro/3CLpro) and Human Cathepsin-L
Elisa Costanzi, Maria Kuzikov, Francesca Esposito, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 21, pp. 11779-11779
Open Access | Times Cited: 71
A structural view of the SARS-CoV-2 virus and its assembly
Nathan J. Hardenbrook, Peijun Zhang
Current Opinion in Virology (2021) Vol. 52, pp. 123-134
Open Access | Times Cited: 65
Potential Resistance of SARS-CoV-2 Main Protease (Mpro) against Protease Inhibitors: Lessons Learned from HIV-1 Protease
János András Mótyán, Mohamed Mahdi, Gyula Hoffka, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 7, pp. 3507-3507
Open Access | Times Cited: 61
Non-covalent SARS-CoV-2 Mpro inhibitors developed from in silico screen hits
Giacomo G. Rossetti, Marianna Ossorio, S. Rempel, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 59
Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses
Judith M. White, Joshua T. Schiffer, Rachel Bender Ignacio, et al.
mBio (2021) Vol. 12, Iss. 6
Open Access | Times Cited: 57
Antiviral cyclic peptides targeting the main protease of SARS-CoV-2
Jason Johansen‐Leete, Sven Ullrich, Sarah E. Fry, et al.
Chemical Science (2022) Vol. 13, Iss. 13, pp. 3826-3836
Open Access | Times Cited: 48
The substitutions L50F, E166A and L167F in SARS-CoV-2 3CLpro are selected by a protease inhibitorin vitroand confer resistance to nirmatrelvir
Dirk Jochmans, Liu C, Kim Donckers, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 42
A Systematic Review of the Global Intervention for SARS-CoV-2 Combating: From Drugs Repurposing to Molnupiravir Approval
Nada A. Ashour, Ayman Abo Elmaaty, Amany A. Sarhan, et al.
Drug Design Development and Therapy (2022) Vol. Volume 16, pp. 685-715
Open Access | Times Cited: 40
The Combination of Molnupiravir with Nirmatrelvir or GC376 Has a Synergic Role in the Inhibition of SARS-CoV-2 Replication In Vitro
Anna Gidari, Samuele Sabbatini, Elisabetta Schiaroli, et al.
Microorganisms (2022) Vol. 10, Iss. 7, pp. 1475-1475
Open Access | Times Cited: 38
Peptidomimetic nitrile warheads as SARS-CoV-2 3CL protease inhibitors
Bing Bai, Elena Arutyunova, Muhammad Bashir Khan, et al.
RSC Medicinal Chemistry (2021) Vol. 12, Iss. 10, pp. 1722-1730
Open Access | Times Cited: 49
Races of small molecule clinical trials for the treatment of COVID‐19: An up‐to‐date comprehensive review
Suwen Hu, Songwei Jiang, Qi Xiang, et al.
Drug Development Research (2021) Vol. 83, Iss. 1, pp. 16-54
Open Access | Times Cited: 46
A Review of the Current Landscape of SARS-CoV-2 Main Protease Inhibitors: Have We Hit the Bullseye Yet?
Guillem Macip, Pol Garcia‐Segura, Júlia Mestres‐Truyol, et al.
International Journal of Molecular Sciences (2021) Vol. 23, Iss. 1, pp. 259-259
Open Access | Times Cited: 41
Progress on SARS-CoV-2 3CLpro Inhibitors: Inspiration from SARS-CoV 3CLpro Peptidomimetics and Small-Molecule Anti-Inflammatory Compounds
Jiajie Zhu, Haiyan Zhang, Qinghong Lin, et al.
Drug Design Development and Therapy (2022) Vol. Volume 16, pp. 1067-1082
Open Access | Times Cited: 35
Protein structure-based in-silico approaches to drug discovery: Guide to COVID-19 therapeutics
Yash Gupta, Oleksandr V. Savytskyi, Matt Coban, et al.
Molecular Aspects of Medicine (2022) Vol. 91, pp. 101151-101151
Open Access | Times Cited: 30
COVID-19 and the promise of small molecule therapeutics: Are there lessons to be learnt?
Wei Shen Ho, Ruirui Zhang, Yeong Lan Tan, et al.
Pharmacological Research (2022) Vol. 179, pp. 106201-106201
Open Access | Times Cited: 29
Page 1 - Next Page

Scroll to top